Clinical data | |
---|---|
Trade names | Lullan |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 92%[1] |
Metabolism | Hepatic[1] |
Elimination half-life | 1.9–2.5 hours[1][2] |
Excretion | Renal (0.4% as unchanged drug)[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H30N4O2S |
Molar mass | 426.58 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Perospirone (Lullan) is an atypical antipsychotic of the azapirone family.[1] It was introduced in Japan by Dainippon Sumitomo Pharma in 2001 for the treatment of schizophrenia and acute cases of bipolar mania.[3][4]